PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsDurvalumab
Imfinzi(durvalumab)
Imfinzi (durvalumab) is an antibody pharmaceutical. Durvalumab was first approved as Imfinzi on 2017-05-01. It is used to treat transitional cell carcinoma in the USA. It has been approved in Europe to treat non-small-cell lung carcinoma. The pharmaceutical is active against programmed cell death 1 ligand 1.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
respiratory tract diseasesD012140
Trade Name
FDA
EMA
Imfinzi
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Durvalumab
Tradename
Proper name
Company
Number
Date
Products
ImfinzidurvalumabAstraZenecaN-761069 RX2017-05-01
2 products
Labels
FDA
EMA
Brand Name
Status
Last Update
imfinziBiologic Licensing Application2025-03-28
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
transitional cell carcinomaD002295
Agency Specific
FDA
EMA
Expiration
Code
durvalumab, Imfinzi, AstraZeneca UK Ltd
2029-10-21Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
L01: Antineoplastic agents
L01F: Monoclonal antibodies and antibody drug conjugates
L01FF: Pd-1/pdl-1 (programmed cell death protein 1/death ligand 1) inhibitors
L01FF03: Durvalumab
HCPCS
Code
Description
J9173
Injection, durvalumab, 10 mg
Clinical
Clinical Trials
856 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD0022894211738323209
Lung neoplasmsD008175C34.903710916219167
NeoplasmsD009369C80524522792
Neoplasm metastasisD009362EFO_00097081192120
PneumoniaD011014EFO_0003106J181113
OncogenesD009857112
Meningeal carcinomatosisD055756EFO_100101211
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CarcinomaD002277C80.04184137126
Small cell lung carcinomaD0557521545101177
Hepatocellular carcinomaD006528C22.01548101176
Liver neoplasmsD008113EFO_1001513C22.016448766
Breast neoplasmsD001943EFO_0003869C5032434165
Squamous cell carcinoma of head and neckD00007719518253140
Squamous cell carcinomaD00229420223238
Biliary tract neoplasmsD001661C24.99256338
Urinary bladder neoplasmsD001749C671127537
CholangiocarcinomaD018281C22.1627132
Show 23 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD015179172837
Pancreatic neoplasmsD010190EFO_0003860C25192635
AdenocarcinomaD000230123135
Triple negative breast neoplasmsD064726142129
MelanomaD0085451211221
LymphomaD008223C85.911917
Esophageal neoplasmsD004938C1561416
Prostatic neoplasmsD011471C6161215
Stomach neoplasmsD013274EFO_0003897C1671315
Ovarian epithelial carcinomaD00007721661215
Show 123 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDurvalumab
INNdurvalumab
Description
Durvalumab (human mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
>5X8M:B|durvalumab heavy chain EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLY LQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTV SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTHHHHHH >5X8M:C|durvalumab light chain EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLE PEDFAVYYCQQYGSLPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Identifiers
PDB5X8M, 5XJ4
CAS-ID
RxCUI
ChEMBL IDCHEMBL3301587
ChEBI ID
PubChem CID
DrugBankDB11714
UNII ID28X28X9OKV (ChemIDplus, GSRS)
Target
Agency Approved
CD274
CD274
Organism
Homo sapiens
Gene name
CD274
Gene synonyms
B7H1, PDCD1L1, PDCD1LG1, PDL1
NCBI Gene ID
Protein name
programmed cell death 1 ligand 1
Protein synonyms
B7 homolog 1, B7-H1, CD274, CD274 antigen, PDCD1 ligand 1
Uniprot ID
Mouse ortholog
Cd274 (60533)
programmed cell death 1 ligand 1 (Q9EP73)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
£
Imfinzi AstraZeneca
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 24,030 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
16,889 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use